Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial
出版年份 2021 全文链接
标题
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial
作者
关键词
-
出版物
Lancet Respiratory Medicine
Volume -, Issue -, Pages -
出版商
Elsevier BV
发表日期
2021-09-02
DOI
10.1016/s2213-2600(21)00331-3
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy
- (2021) Linda Petrone et al. JOURNAL OF INFECTION
- Baricitinib Therapy in Covid-19 Pneumonia — An Unmet Need Fulfilled
- (2021) Delia Goletti et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of high dose of baricitinib in severe COVID-19 pneumonia: a prospective cohort study in Bangladesh
- (2021) Md. Jahidul Hasan et al. BMC INFECTIOUS DISEASES
- Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
- (2021) Obbina Abani et al. LANCET
- Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia
- (2021) Patrícia O. Guimarães et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China
- (2020) Qiurong Ruan et al. INTENSIVE CARE MEDICINE
- Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
- (2020) Peter Richardson et al. LANCET
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
- (2020) Chaolin Huang et al. LANCET
- COVID-19: combining antiviral and anti-inflammatory treatments
- (2020) Justin Stebbing et al. LANCET INFECTIOUS DISEASES
- Mechanism of baricitinib supports artificial intelligence‐predicted testing in COVID‐19 patients
- (2020) Justin Stebbing et al. EMBO Molecular Medicine
- Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial
- (2020) Yang Cao et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposal
- (2020) Hasan K. Siddiqi et al. JOURNAL OF HEART AND LUNG TRANSPLANTATION
- Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact
- (2020) Fabrizio Cantini et al. JOURNAL OF INFECTION
- Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
- (2020) Fei Zhou et al. LANCET
- Remdesivir for the Treatment of Covid-19 — Preliminary Report
- (2020) John H. Beigel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Use of Baricitinib in Patients with Moderate and Severe COVID-19
- (2020) Boghuma K Titanji et al. CLINICAL INFECTIOUS DISEASES
- Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study
- (2020) Fabrizio Cantini et al. JOURNAL OF INFECTION
- Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report
- (2020) NEW ENGLAND JOURNAL OF MEDICINE
- Characterization of the cytokine storm reflects hyperinflammatory endothelial dysfunction in COVID-19
- (2020) Jonathan T. Sims et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
- (2020) Andre C. Kalil et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies
- (2018) Gina A. Montealegre Sanchez et al. JOURNAL OF CLINICAL INVESTIGATION
- Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study
- (2016) Y. Tanaka et al. JOURNAL OF RHEUMATOLOGY
- The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers
- (2014) Jack G. Shi et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050
- (2010) J. S. Fridman et al. JOURNAL OF IMMUNOLOGY
- Sample Size Re-Estimation for Adaptive Sequential Design in Clinical Trials
- (2008) Ping Gao et al. Journal of Biopharmaceutical Statistics
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now